Methods for treating brain metastasis

Patent metadata

Field	Value
Publication number	US-11058665-B2
Application number	US-201916570180-A
Country	US
Kind code	B2
Filing date	Sep 13, 2019
Priority date	Sep 19, 2014
Publication date	Jul 13, 2021
Grant date	Jul 13, 2021

Abstract

The present invention relates to methods for treating brain metastasis by inhibiting gap junction functionality. It is based, at least in part, on the discovery that cancer cells expressing Protocadherin 7 and Connexin 43 form gap junctions with astrocytes that promote the growth of brain metastases, and that inhibition of Protocadherin 7 and/or Connexin 43 expression in cancer cells reduce progression of brain metastases. It is further based on the discovery that treatment with gap junction inhibitors tonabersat and meclofenamate inhibited progression of brain metastatic lesions and enhanced the anti-cancer activity of the conventional chemotherapeutic agent, carboplatin.

First claim

What is claimed is:

1. A method for treating a cancer that has metastasized to the brain in a subject, comprising: administering to the subject tonabersat.

2. The method of claim 1 , wherein the tonabersat is administered in an amount of about 10 mg/kg.

3. The method of claim 1 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.

4. The method of claim 1 , wherein the cancer is a breast cancer or a lung cancer.

5. The method of claim 1 , further comprising administering to the subject an anti-cancer agent.

6. The method of claim 5 , wherein the anti-cancer agent is carboplatin.

7. The method of claim 6 , wherein the carboplatin is administered in an amount of between 4 mg/kg and about 6 mg/kg.

8. A method for preventing and/or inhibiting the metastasis of a cancer to the brain in a subject, comprising: administering to the subject tonabersat.

9. The method of claim 8 , wherein the tonabersat is administered in an amount of about 10 mg/kg.

10. The method of claim 8 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.

11. The method of claim 8 , wherein the cancer is a breast cancer or a lung cancer.

12. The method of claim 8 , further comprising administering to the subject an anti-cancer agent.

13. The method of claim 12 , wherein the anti-cancer agent is carboplatin.

14. The method of claim 13 , wherein the carboplatin is administered in an amount of between 4 mg/kg and about 6 mg/kg.

15. A method for reducing the risk of the metastasis of a cancer to the brain in a subject, comprising: administering to the subject tonabersat.

16. The method of claim 15 , wherein tonabersat is administered in an amount of about 10 mg/kg.

17. The method of claim 15 , wherein the tonabersat is administered in an amount of between about 0.8 mg/kg and about 1.2 mg/kg.

18. The method of claim 15 , wherein the cancer is a breast cancer or a lung cancer.

19. The method of claim 15 , further comprising administering to the subject an anti-cancer agent.

20. The method of claim 19 , wherein the anti-cancer agent is carboplatin.

Assignees

• Memorial Sloan Kettering Cancer Center

Inventors

• Massague Joan
• Boire Adrienne
• Chen Qing

Classifications

• A61K31/353 Primary

  3,4-Dihydrobenzopyrans, e.g. chroman, catechin · CPC title

• A61K31/555

  containing heavy metals, e.g. hemin, hematin, melarsoprol · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• G01N33/5011

  for testing antineoplastic activity · CPC title

• A61P35/00

  Antineoplastic agents · CPC title